Results 1 to 10 of about 509,743 (335)

Increasing Awareness of Soft-Tissue Sarcoma: Podcast of a Patient–HCP Discussion [PDF]

Oncology and Therapy
Soft-tissue sarcoma is a rare cancer, making up less than 1% of new cancer diagnoses. They comprise tumours of the connective tissue, and as such can arise in any part of the body and can mimic other conditions. In addition, there are over 80 subtypes of
Gillian Faskin, Sam Hackett
doaj   +2 more sources

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications

Experimental Hematology & Oncology, 2023
Soft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment options. ATR inhibition already showed an activity,
M Spalato-Ceruso, A Laroche-Clary, R Perret, Y Valverde, V Chaire, Marie-Alix Derieppe, V Velasco, A Bourdon, A Italiano   +8 more
doaj   +1 more source

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

Frontiers in Oncology, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Sant P. Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari, Nadezhda Omelchenko, Stefan Makrievski, Don A. Brigham, Don A. Brigham, Victoria Chua-Alcala, Doris Quon, Ania Moradkhani, Erlinda M. Gordon, Erlinda M. Gordon   +13 more
doaj   +1 more source

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

ESMO Open, 2020
Background Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II ...
Etienne Rouleau, Axel Le Cesne, Olivier Mir, Pierre Méeus, Julien Adam, Alice Boilève, Armelle Dufresne, Ali Chamseddine, Elise Nassif, Sarah Dumont, Medhi Brahmi, Marie Karanian, Véronique Haddad, Matthieu Faron, Charles Honoré   +14 more
doaj   +1 more source

What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland

JCO Global Oncology, 2021
PURPOSEIn Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care.
Holly M. McCabe, Alannah Smrke, Fiona Cowie, Jeff White, Peter Chong, Steven Lo, Ashish Mahendra, Sanjay Gupta, Michelle Ferguson, David Boddie, Walter Mmekka, Lorraine Stirling, Lindsay Campbell, Robin L. Jones, Ioanna Nixon   +14 more
doaj   +1 more source

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. [PDF]

, 2016
Synovial sarcoma is an aggressive soft tissue sarcoma genetically defined by the fusion oncogene SS18-SSX. It is hypothesized that either SS18-SSX disrupts SWI/SNF complex inhibition of the polycomb complex 2 (PRC2) methyltransferase Enhancer of Zeste ...
Choy, Edwin, Cote, Gregory M, Duan, Zhenfeng, Gao, Yan, Hornicek, Francis J, Mankin, Henry J, Shen, Jacson K   +6 more
core   +2 more sources

Age-related sarcoma patient experience: results from a national survey in England

BMC Cancer, 2018
Background Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers.
Eugenie Younger, Olga Husson, Lindsey Bennister, Jeremy Whelan, Roger Wilson, Andy Roast, Robin L Jones, Winette TA van der Graaf   +7 more
doaj   +1 more source

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. [PDF]

, 2014
BackgroundIncreasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as tyrosine kinase inhibitors ...
Ames, Erik, Borys, Dariusz, Canter, Robert J, Chen, Mingyi, Grossenbacher, Steven K, Li, Chin-Shang, Mac, Stephanie, Monjazeb, Arta M, Murphy, William J, Sayers, Thomas J, Smith, Rachel C, Tellez, Joe   +11 more
core   +2 more sources

Rare aggressive behavior of MDM2-amplified retroperitoneal dedifferentiated liposarcoma, with brain, lung and subcutaneous metastases

Rare Tumors, 2016
Dedifferentiated liposarcoma (DDL) is a histologically pleomorphic sarcoma, traditionally defined as well-differentiated liposarcoma with abrupt transition to high grade, nonlipogenic sarcoma.
Imen Ben Salha, Shane Zaidi, Jonathan Noujaim, Aisha B. Miah, Cyril Fisher, Robin L. Jones, Khin Thway   +6 more
doaj   +1 more source

Associations of clock genes polymorphisms with soft tissue sarcoma susceptibility and prognosis [PDF]

, 2018
BACKGROUND: Dysfunction of the circadian clock and polymorphisms of some circadian genes have been linked to cancer development and progression. We investigated the relationship between circadian genes germline variation and susceptibility or prognosis ...
Benna, Clara, Del Fiore, Paolo, Mocellin, Simone, Rajendran, Senthilkumar, Rossi, Carlo Riccardo, Spiro, Giovanna, Tropea, Saveria   +6 more
core   +2 more sources